Annals of Surgical Oncology

, Volume 14, Issue 10, pp 3011–3018 | Cite as

Anaplastic Carcinoma of the Thyroid Arising More Often from Follicular Carcinoma than Papillary Carcinoma

  • Hwei-Ming Wang
  • Yu-Wen Huang
  • Jen-Seng Huang
  • Cheng-Hsu Wang
  • Victor C. Kok
  • Chao-Ming Hung
  • Han-Ming Chen
  • Chin-Yuan Tzen
Endocrine Tumors

Abstract

Background

Anaplastic thyroid carcinoma (ATC), a rare and highly malignant tumor, has long been thought to arise from well-differentiated carcinoma (WDC) such as follicular thyroid carcinoma (FTC) and papillary thyroid carcinoma (PTC). The purpose of this study was to test this notion by examining whether and, if so, how often ATC harbors the oncogenes that are commonly associated with WDC, such as RAS in FTC and BRAF in PTC.

Methods

We analyzed the mutation hotspots of BRAF (codon 600) and N-, K-, and H-RAS (codons 12, 13, and 61) in 16 ATCs. We also examined two genes, PIK3CA (exons 9 and 20) and TP53 (exons 5–9), both of which have been reported in ATCs.

Results

The results showed that approximately 31% (5 of 16) of ATCs harbored N-RAS mutation, 6% (1 of 16) had mutated BRAF, and approximately 56% (9 of 16) had mutated TP53. As to the three ATCs that had coexisted PTCs, mutated BRAF was detected in all PTC components but only in one ATC, while mutated PIK3CA was found in only one PTC component but not in the ATC.

Conclusion

A number of ATCs arise from WDCs, more often from RAS-mutant tumors than from BRAF-mutant tumors, implying that particular attention should be paid to the WDC harboring RAS mutation.

Keywords

Anaplastic thyroid carcinoma Follicular thyroid carcinoma Papillary thyroid carcinoma BRAF mutation N-RAS mutation TP53 mutation 

References

  1. 1.
    Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993; 328:553–9PubMedCrossRefGoogle Scholar
  2. 2.
    Schmutzler C, Koehrle J. Innovative strategies for the treatment of thyroid cancer. Eur J Endocrinol 2000; 143:15–24PubMedCrossRefGoogle Scholar
  3. 3.
    Chan JKC. Tumors of the thyroid and parathyroid glands. In: Fletcher CDM (ed.) Diagnostic Histopathology of Tumors. Churchill Livingstone, 2007:998Google Scholar
  4. 4.
    Rosai J, Carcangiu ML, DeLellis RA. Undifferentiated (anaplastic) carcinoma. In: Rosai J, Sobin LH (eds.) Atlas of Tumor Pathology: Tumors of the Thyroid Gland. Washington, DC: AFIP. 1992:154Google Scholar
  5. 5.
    Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003; 95:625–7PubMedCrossRefGoogle Scholar
  6. 6.
    Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003; 22:4578–80PubMedCrossRefGoogle Scholar
  7. 7.
    Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003; 88:4393–7PubMedCrossRefGoogle Scholar
  8. 8.
    Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003; 63:4561–7PubMedGoogle Scholar
  9. 9.
    Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63:1454–7PubMedGoogle Scholar
  10. 10.
    Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003; 88:2318–26PubMedCrossRefGoogle Scholar
  11. 11.
    Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 1990; 4:1474–9PubMedGoogle Scholar
  12. 12.
    Capella G, Matias-Guiu X, Ampudia X, de Leiva A, Perucho M, Prat J. Ras oncogene mutations in thyroid tumors: polymerase chain reaction-restriction-fragment-length polymorphism analysis from paraffin-embedded tissues. Diagn Mol Pathol 1996; 5:45–52PubMedCrossRefGoogle Scholar
  13. 13.
    Adeniran AJ, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 2006; 30:216–22PubMedCrossRefGoogle Scholar
  14. 14.
    García-Rostán G, Costa AM, Pereira-Castro I. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 2005; 65:10199–207PubMedCrossRefGoogle Scholar
  15. 15.
    Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993; 91:179–84PubMedGoogle Scholar
  16. 16.
    Tzen CY, Huang YW, Fu YS. Is atypical follicular adenoma of the thyroid a preinvasive malignancy? Hum Pathol 2003; 34:666–9PubMedCrossRefGoogle Scholar
  17. 17.
    Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63:1454–7PubMedGoogle Scholar
  18. 18.
    Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 2003; 88:2745–52PubMedCrossRefGoogle Scholar
  19. 19.
    LiVolsi VA, Asa SL. The demise of follicular carcinoma of the thyroid gland. Thyroid 1994; 4:233–6PubMedGoogle Scholar
  20. 20.
    Di Cristofaro J, Marcy M, Vasko V, Sebag F, Fakhry N, Wynford-Thomas D, De Micco C. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant. Hum Pathol 2006; 37:824–30PubMedCrossRefGoogle Scholar
  21. 21.
    García-Rostán G, Zhao H, Camp RL, et al. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 2003; 21:3226–35PubMedCrossRefGoogle Scholar
  22. 22.
    Hou P, Liu D, Shan Y, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 2007; 13:1161–70PubMedCrossRefGoogle Scholar
  23. 23.
    Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003; 88:5399–404PubMedCrossRefGoogle Scholar
  24. 24.
    Soares P, Trovisco V, Rocha AS, et al. BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch 2004; 444:572–6PubMedCrossRefGoogle Scholar
  25. 25.
    Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D, Westra WH. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol 2004; 17:1359–63PubMedCrossRefGoogle Scholar
  26. 26.
    Xing M, Vasko V, Tallini G, et al. BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab 2004; 89:1365–8PubMedCrossRefGoogle Scholar
  27. 27.
    Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 2005; 103:2261–8PubMedCrossRefGoogle Scholar
  28. 28.
    Basolo F, Pisaturo F, Pollina LE, et al. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid 2000; 10:19–23PubMedCrossRefGoogle Scholar
  29. 29.
    Fukushima T, Suzuki S, Mashiko M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003; 22:6455–7PubMedCrossRefGoogle Scholar
  30. 30.
    Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 1993; 91:1753–60PubMedCrossRefGoogle Scholar
  31. 31.
    Ito T, Seyama T, Mizuno T, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 1992; 52:1369–71PubMedGoogle Scholar
  32. 32.
    Zou M, Shi Y, Farid NR. p53 mutations in all stages of thyroid carcinomas. J Clin Endocrinol Metab 1993; 77:1054–8PubMedCrossRefGoogle Scholar
  33. 33.
    Ho YS, Tseng SC, Chin TY, Hsieh LL, Lin JD. p53 gene mutation in thyroid carcinoma. Cancer Lett 1996; 103:57–63PubMedCrossRefGoogle Scholar
  34. 34.
    Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L, Beck-Peccoz P. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 2004; 61:239–43CrossRefGoogle Scholar
  35. 35.
    Liu RT, Hou CY, You HL, et al. Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan. Thyroid 2004; 14:616–21PubMedCrossRefGoogle Scholar
  36. 36.
    Esapa CT, Johnson SJ, Kendall-Taylor P, Lennard TW, Harris PE. Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf) 1999; 50:529–35CrossRefGoogle Scholar
  37. 37.
    Puxeddu E, Moretti S, Elisei R, et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004; 89:2414–20PubMedCrossRefGoogle Scholar
  38. 38.
    Shi YF, Zou MJ, Schmidt H, Juhasz F, Stensky V, Robb D, Farid NR. High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area. Cancer Res 1991; 51:2690–3PubMedGoogle Scholar
  39. 39.
    Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 2003; 120:71–7PubMedCrossRefGoogle Scholar
  40. 40.
    DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. World Health Organization Classification of Tumours: Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press, 2004Google Scholar
  41. 41.
    Harach HR, Escalante DA, Day ES. Thyroid cancer and thyroiditis in Salta, Argentina: a 40-yr study in relation to iodine prophylaxis. Endocr Pathol 2002; 13:175–81PubMedCrossRefGoogle Scholar
  42. 42.
    Wymann MP, Pirola L. Structure and function of phosphoinositide 3-kinases. Biochim Biophys Acta 1998; 1436:127–50PubMedGoogle Scholar
  43. 43.
    Varley JM, Attwooll C, White G, et al. Characterization of germline TP53 splicing mutations and their genetic and functional analysis. Oncogene 2001; 20:2647–54PubMedCrossRefGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2007

Authors and Affiliations

  • Hwei-Ming Wang
    • 1
  • Yu-Wen Huang
    • 2
  • Jen-Seng Huang
    • 3
  • Cheng-Hsu Wang
    • 3
  • Victor C. Kok
    • 4
  • Chao-Ming Hung
    • 5
  • Han-Ming Chen
    • 6
  • Chin-Yuan Tzen
    • 7
    • 8
    • 9
  1. 1.Division of Colorectal Surgery, Department of SurgeryTaichung Veterans General HospitalTaichungTaiwan
  2. 2.Department of Medical ResearchMackay Memorial HospitalTaipeiTaiwan
  3. 3.Division of Hematology/Oncology, Department of Internal MedicineChang Gung Memorial HospitalKeelungTaiwan
  4. 4.Division of Medical OncologyKuang Tien General HospitalTaichungTaiwan
  5. 5.Department of General SurgeryE-da HospitalKaoshiungTaiwan
  6. 6.Department of SurgeryTen-Chan HospitalTaoyuanTaiwan
  7. 7.Department of PathologyMackay Memorial HospitalTaipeiTaiwan
  8. 8.Mackay Medicine, Nursing and Management CollegeTaipeiTaiwan
  9. 9.National Taipei College of NursingTaipeiTaiwan

Personalised recommendations